PRTC News and Press, PureTech Health plc

Presentations to highlight differentiated approach to advancing deupirfenidone, reinforcing its potential to serve as a new standard of care within the evolving idiopathic pulmonary fibrosis treatment landscape PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Comp...

2026-04-29 16:01:42 ET PureTech Health plc (PRTC) Q4 2025 Earnings Call April 29, 2026 9:00 AM EDT Company Participants Allison Talbot - Senior VP of Communications & Head of Investor Relations Robert Lyne - CEO & Director Eric Elenko - Co-Founder & Pre...

2026-04-29 02:50:02 ET More on PureTech Neuropsychiatric drug developer Seaport files for U.S. IPO Historical earnings data for PureTech Financial information for PureTech Read the full article on Seeking Alpha For further details see: PureTech re...

Refined strategy and disciplined execution position Company to unlock value from its portfolio, which includes Celea Therapeutics’ Phase 3-ready deupirfenidone for idiopathic pulmonary fibrosis, Gallop Oncology’s clinically-validated LYT-200 for myeloid malignancies, and Seaport The...

PureTech to maintain its primary listing on the London Stock Exchange Simplification of listing structure expected to enhance operational efficiency and focus resources on advancing the Company’s portfolio PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the appointment of Dr. Sharon Mat...

Phase 1b dataset with LYT-200 demonstrates complete responses and favorable tolerability across both R/R HR-MDS and R/R AML PureTech’s Founded Entity, Gallop Oncology, to advance LYT-200 first in R/R HR-MDS, with continued development planned in R/R AML Company plans to eng...

2026-04-21 12:45:14 ET Image source: The Motley Fool. Aug. 28, 2025 at 9:00 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2025, on Wednesday, April 29, 2026. A presentation and conference call to discuss the results will take place at ...

2026-04-11 13:11:42 ET More on Seaport Therapeutics, Inc. Financial information for Seaport Therapeutics, Inc. Read the full article on Seeking Alpha For further details see: Neuropsychiatric drug developer Seaport files for U.S. IPO